Machine signal
Active cluster sell — 3 distinct insiders, $2M, window ends Aug 13, 2026.
Figures computed from official regulatory filings — .
Analysttarget 88 USD (+261%) · consensus 5/5 · 3 buy · 0 hold · 0 sell
Ownershipinsiders 9.44% · institutions 22.83% · short 4.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cue Biopharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
42 buys37 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Sarraf Pashatrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Garzone Pamela | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Meluzio Michael Vincent | Sell | $44.6K | SEC |
| Meluzio Michael Vincent | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ray Sumita | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Meluzio Michael Vincent | Sell | $124.6K | SEC |
| Ray Sumita | Sell | $70K | SEC |
| Ray Sumita | Sell | $124.5 | SEC |
| Meluzio Michael Vincent | Sell | $93.4 | SEC |
| Ray Sumita | Sell | $195.5K | SEC |
| Ray Sumita | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Meluzio Michael Vincent | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Shao-Lee | Sell | $923.7K | Unusual size | SEC |
| Lin Shao-Lee | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Shao-Lee | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Shao-Lee | Sell | $160.3K | Unusual size | SEC |
| Lin Shao-Lee | Sell | $308.4K | SEC |
| Lin Shao-Lee | Sell | $147.5K | SEC |
| Lin Shao-Lee | Sell | $66.8K | SEC |
| Ahlers James M | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ahlers James M | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Shao-Lee | AwardD (derivative) | $1M | SEC |
| Lin Shao-Lee | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Borie Dominique Christian | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Borie Dominique Christian | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |